A Phase 1b Study of the Anti-Cancer Stem Cell Agent Demcizumab, Pemetrexed and Carboplatin in Patients with Non-Squamous Non-Small Cell Lung Cancer (NSCLC) 1McKeage D,

First Page		Document Content
Date: 2016-06-04 05:54:29 Monoclonal antibodies Antifolates Benzamides Eli Lilly and Company Pemetrexed Chemotherapy Cancer stem cell CHOP Demcizumab		A Phase 1b Study of the Anti-Cancer Stem Cell Agent Demcizumab, Pemetrexed and Carboplatin in Patients with Non-Squamous Non-Small Cell Lung Cancer (NSCLC) 1McKeage D, Add to Reading List Source URL: s3.amazonaws.com Download Document from Source Website File Size: 571,30 KB Share Document on Facebook

	Effect of Pemetrexed Alone or Pemetrexed-Cisplatin Regimens on the Liver and Renal Parameters in Adult Cancer Patients DocID: 1uZLR - View Document
	A Phase 1b Study of the Anti-Cancer Stem Cell Agent Demcizumab, Pemetrexed and Carboplatin in Patients with Non-Squamous Non-Small Cell Lung Cancer (NSCLC) 1 Stagg R, DocID: 1t7Mt - View Document
	A Phase 1b Study of the Anti-Cancer Stem Cell Agent Demcizumab, Pemetrexed and Carboplatin in Patients with Non-Squamous Non-Small Cell Lung Cancer (NSCLC) 1McKeage D, DocID: 1pDVR - View Document
	Schedule of Pharmaceutical Benefits Efficient Funding of Chemotherapy Effective 1 August 2016 DocID: 1pbaD - View Document
	HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use GILOTRIF safely and effectively. See full prescribing information for GILOTRIF. ® DocID: 1oOLG - View Document